Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making
Merck, WuXi BD alum Tong Zhang readies his tool kit to partner assets with roots in China’s hospitals
A BD alum of Merck and WuXi, Tong Zhang readies his partnering tool kit to partner Shanghai company’s innovative assets with roots in China’s hospitals.
A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years.
Shanghai Genechem Co. Ltd. and I-Mab Biopharma (NASDAQ:IMAB) on April 6 partnered to develop and commercialize bispecific antibodies based on mAbs developed by Genechem and antibodies selected by I-Mab. Terms of the deal were not disclosed.